Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease.

Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. Postepy Dermatol Alergol. 2019 Apr;36(2):239-241 Authors: Kupryś-Lipińska I, Pałczyński C, Molinska J, Kuna P PMID: 31320863 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research

Related Links:

Authors: Cavaliere C, Frati F, Ridolo E, Greco A, de Vincentiis M, Masieri S, Makri E, Incorvaia C Abstract Introduction: The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils production, activation, and survival, which is associated with the eosinophilic asthma phenotype, as well as with other disorders characterized by high levels of eosinophils. Areas covered: All the available literature on the outcomes treatment with mepolizumab in eosinophilic disorders are reviewed, including asthma, ch...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
AbstractBackgroundFunctional limitations may be more common in middle-aged adults than previously recognized. However, there are few published data on the prevalence of activity limitations, and their association with multimorbidity, among adults 50 to 64  years old.ObjectiveTo describe the prevalence of activity limitations and the association with multimorbidity in middle-aged adults.DesignCross-sectional analysis of US population-based National Health and Nutrition Examination Survey (NHANES) 2011 –2016.ParticipantsThe total number of community-dwelling NHANES participants aged 50 –64 years old is ...
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
We report a collaborative initiative in a large metropolis.MethodsTo assess on a structural basis the rate of utilization as well as efficacy and safety parameters of 2 ECCO2R devices in 10 intensive care units (ICU) during a 2-year period.ResultsSeventy patients were recruited in 10 voluntary and specifically trained centers. The median utilization rate was 0.19 patient/month/center (min 0.04; max 1.20). ECCO2R was started under invasive mechanical ventilation (IMV) in 59 patients and non-invasive ventilation in 11 patients. The Hemolung Respiratory Assist System (Alung) was used in 53 patients and the iLA Activve iLA kit...
Source: Journal of Intensive Care - Category: Intensive Care Source Type: research
PMID: 31426658 [PubMed - as supplied by publisher]
Source: Chronic Illness - Category: General Medicine Authors: Tags: Chronic Illn Source Type: research
Conclusions: The ACO cohort with statin use exhibited the lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, the hepatic, renal and heart failure were less frequent.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Condition:   COPD, Asthma,ACO Intervention:   Biological: sputum cytology Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD, Asthma,ACO Intervention:   Biological: sputum cytology Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD, Asthma,ACO Intervention:   Biological: sputum cytology Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD, Asthma,ACO Intervention:   Biological: sputum cytology Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD, Asthma,ACO Intervention:   Biological: sputum cytology Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asthma | Chronic Obstructive Pulmonary | Dermatology | Skin | Xolair